文献速递肿瘤 PET/CT

68Ga-FAPI-LM3异双价分子的设计、临床前评估及用于鼻咽癌PET显像的临床转化

Design, Preclinical Evaluation, and Clinical Translation of 68Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma.
PubMed 文献 · J Nucl Med · 2024-03-01

研究设计并合成靶向FAP和SSTR2的68Ga-FAPI-LM3异双价分子,在HT-1080-FAP和HT-1080-SSTR2荷瘤小鼠中行小动物PET与生物分布评估,并在6例鼻咽癌患者中与18F-FDG PET/CT比较,显示原发及转移灶摄取更高、病灶检出与肿瘤勾画改善。

要点

  • 68Ga-FAPI-LM3对FAP和SSTR2均具高亲和力,双靶点结合特性在体外和体内均得到验证。
  • 在HT-1080-FAP联合HT-1080-SSTR2荷瘤模型中,68Ga-FAPI-LM3肿瘤摄取显著高于68Ga-FAPI-46和68Ga-DOTA-LM3。
  • 6例鼻咽癌患者中,68Ga-FAPI-LM3 PET/CT在原发和转移灶的摄取显著高于18F-FDG,病灶检出和肿瘤勾画更优。

核心结论

  • 68Ga-FAPI-LM3在体外和体内均表现出FAP与SSTR2双受体靶向特性,与单体68Ga-FAPI和68Ga-DOTA-LM3相比肿瘤摄取和滞留改善。
  • 本研究凸显68Ga-FAPI-LM3 PET/CT用于鼻咽癌显像的临床可行性。

研究设计与样本

  • 基于FAPI-46和LM3的结构设计并合成FAPI-LM3,经68Ga标记后在体外和体内评估双受体结合亲和力。
  • 在HT-1080-FAP和HT-1080-SSTR2肿瘤异种移植模型上开展小动物PET和生物分布等临床前研究。
  • 在鼻咽癌患者中评估68Ga-FAPI-LM3 PET/CT的临床可行性,并与18F-FDG结果比较,临床研究纳入6例鼻咽癌患者。

主要发现

  • 68Ga-FAPI-LM3对FAP和SSTR2均显示高亲和力。
  • 在HT-1080-FAP联合HT-1080-SSTR2肿瘤异种移植模型中,68Ga-FAPI-LM3的肿瘤摄取显著高于68Ga-FAPI-46和68Ga-DOTA-LM3。
  • 在纳入6例鼻咽癌患者的临床研究中,68Ga-FAPI-LM3 PET/CT在原发和转移病灶的摄取显著高于18F-FDG,病灶检出率和肿瘤勾画得到改善。

临床怎么用

  • 原文结论指出本研究凸显68Ga-FAPI-LM3 PET/CT用于鼻咽癌显像的临床可行性,未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Extensive research has been conducted on radiolabeled fibroblast activation protein (FAP) inhibitors (FAPIs) and p-Cl-Phe-cyclo(d-Cys-Tyr-d-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)d-Tyr-NH2 (LM3) peptides for imaging of FAP and somatostatin receptor 2 (SSTR2)-positive tumors. In this study, we designed and synthesized a FAPI-LM3 heterobivalent molecule radiolabeled with 68Ga and evaluated its effectiveness in both tumor xenografts and patients with nasopharyngeal carcinoma (NPC). Methods: The synthesis of FAPI-LM3 was based on the structures of FAPI-46 and LM3. After radiolabeling with 68Ga, its dual-receptor-binding affinity was evaluated in vitro and in vivo. Preclinical studies, including small-animal PET and biodistribution evaluation, were conducted on HT-1080-FAP and HT-1080-SSTR2 tumor xenografts. The feasibility of 68Ga-FAPI-LM3 PET/CT in a clinical setting was evaluated in patients with NPC, and the results were compared with those of 18F-FDG. Results: 68Ga-FAPI-LM3 showed high affinity for both FAP and SSTR2. The tumor uptake of 68Ga-FAPI-LM3 was significantly higher than that of 68Ga-FAPI-46 and 68Ga-DOTA-LM3 in HT-1080-FAP-plus-HT-1080-SSTR2 tumor xenografts. In a clinical study involving 6 NPC patients, 68Ga-FAPI-LM3 PET/CT showed significantly higher uptake than did 18F-FDG in primary and metastatic lesions, leading to enhanced lesion detectability and tumor delineation. Conclusion: 68Ga-FAPI-LM3 exhibited FAPI and SSTR2 dual-receptor-targeting properties both in vitro and in vivo, resulting in improved tumor uptake and retention compared with that observed with monomeric 68Ga-FAPI and 68Ga-DOTA-LM3. This study highlights the clinical feasibility of 68Ga-FAPI-LM3 PET/CT for NPC imaging.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Zhao L, Pang Y, Fang J, et al. Design, Preclinical Evaluation, and Clinical Translation of 68Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma. J Nucl Med. 2024. PMID: 38176714. doi:10.2967/jnumed.123.266183

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。